



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Gemtuzumab ozogamicin

Cat. No.:	HY-109539
CAS No.:	220578-59-6
Target:	Antibody-Drug Conjugates (ADCs); Apoptosis
Pathway:	Antibody-drug Conjugate/ADC Related; Apoptosis
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Gemtuzumab ozogamicin

BIOLOGICAL ACTIVITY

Description	Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic drug Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML) ^{[1][2]} .								
In Vitro	<p>Gemtuzumab ozogamicin (1-250 ng/mL ; 72 hours) has cell cytotoxicity in CD33-positive cells^[1]. Gemtuzumab ozogamicin is an ADC. After binding of the antibody to CD33 and subsequent internalization, Calicheamicin mediates cytotoxicity to CD33-positive myeloid cells primarily through induction of DNA damage and subsequent apoptosis [1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>CD33-positive and CD33-deficient cells (HL60, HL60R, Kasumi-1, MV4-11, MV4-11R, primary CD34-positive HSPCs and primary AML blasts)</td> </tr> <tr> <td>Concentration:</td> <td>0, 1, 5, 10, 25, 50, 100, 250 ng/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Wildtype HL60 exhibited the highest sensitivity to GO (IC₅₀=1.37 ng/mL), and almost all HL60 cells died at 5 ng/mL concentration. HL60R, Kasumi-1, MV4-11 and MV4-11R showed similar sensitivity, with IC₅₀s of 2.28, 3.19, 3.63 and 5.36 ng/mL, respectively. IC₅₀ in CD33-negative HL60R, Kasumi-1, MV4-11 and MV4-11R cells also increased significantly to 95.53, 50.78, 72.74 and 66.8 ng/mL, respectively.</td> </tr> </table>	Cell Line:	CD33-positive and CD33-deficient cells (HL60, HL60R, Kasumi-1, MV4-11, MV4-11R, primary CD34-positive HSPCs and primary AML blasts)	Concentration:	0, 1, 5, 10, 25, 50, 100, 250 ng/mL	Incubation Time:	72 hours	Result:	Wildtype HL60 exhibited the highest sensitivity to GO (IC ₅₀ =1.37 ng/mL), and almost all HL60 cells died at 5 ng/mL concentration. HL60R, Kasumi-1, MV4-11 and MV4-11R showed similar sensitivity, with IC ₅₀ s of 2.28, 3.19, 3.63 and 5.36 ng/mL, respectively. IC ₅₀ in CD33-negative HL60R, Kasumi-1, MV4-11 and MV4-11R cells also increased significantly to 95.53, 50.78, 72.74 and 66.8 ng/mL, respectively.
Cell Line:	CD33-positive and CD33-deficient cells (HL60, HL60R, Kasumi-1, MV4-11, MV4-11R, primary CD34-positive HSPCs and primary AML blasts)								
Concentration:	0, 1, 5, 10, 25, 50, 100, 250 ng/mL								
Incubation Time:	72 hours								
Result:	Wildtype HL60 exhibited the highest sensitivity to GO (IC ₅₀ =1.37 ng/mL), and almost all HL60 cells died at 5 ng/mL concentration. HL60R, Kasumi-1, MV4-11 and MV4-11R showed similar sensitivity, with IC ₅₀ s of 2.28, 3.19, 3.63 and 5.36 ng/mL, respectively. IC ₅₀ in CD33-negative HL60R, Kasumi-1, MV4-11 and MV4-11R cells also increased significantly to 95.53, 50.78, 72.74 and 66.8 ng/mL, respectively.								

REFERENCES

[1]. Yi Liu, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. *Int J Cancer*. 2022 Apr 1;150(7):1141-1155.

[2]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. *Expert Rev Clin Pharmacol*. 2018;11(6):549-559.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA